Dabigatran and left atrial appendage thrombus.

J Thromb Thrombolysis

CASMU Arrhythmia Service, Montevideo, Uruguay.

Published: November 2012

A 59-year-old white woman with previous history of arterial hypertension consulted because of palpitations. Atrial fibrillation of uncertain duration was diagnosed. She was not receiving anticoagulants. A trans-esophageal echocardiogram was performed, and a large left atrial appendage thrombus was detected. A strategy of rate control and anti-vitamin K treatment was started. On the subsequent days, we could not reach therapeutic INRs. Therefore, it was decided to stop warfarin and initiate dabigatran. We describe the evolution of the patient, the thrombus resolution, and a successful electrical cardioversion. In our comments, we summarize the natural history of left atrial thrombus, both with and without anticoagulant therapy. We also discuss the differences between warfarin and dabigatran.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-012-0747-1DOI Listing

Publication Analysis

Top Keywords

left atrial
12
atrial appendage
8
appendage thrombus
8
dabigatran left
4
atrial
4
thrombus
4
thrombus 59-year-old
4
59-year-old white
4
white woman
4
woman previous
4

Similar Publications

Background: The IntellaNav MiFi OI catheter (MiFi) is equipped with a sensor for local impedance (LI) monitoring and three mini-electrodes. In this study, we investigated the target LI values for a successful pulmonary vein isolation (PVI) under the pacing and ablation technique using the MiFi catheter.

Methods: Twenty-seven patients underwent PVI using the MiFi catheter under mini electrode pacing from the MiFi catheter.

View Article and Find Full Text PDF

Objective: To explore the risk factors associated with postoperative atrial fibrillation (POAF) after off-pump coronary artery bypass grafting (OPCABG) and to construct a nomogram predictive model.

Methods: In this retrospective cohort study, clinical data of 193 patients who received OPCABG in Huai'an First People's Hospital Affiliated to Nanjing Medical University from June 2021 to November 2023 were retrospectively analyzed. Based on the established diagnosis of POAF, patients were divided into the POAF group (n=75) and the non-POAF group (n=118).

View Article and Find Full Text PDF

Background: Up to 50% of patients undergoing mitral transcatheter edge-to-edge repair (MTEER) have an indication for left atrial appendage occlusion (LAAO). However, prospective evaluation of this strategy is lacking.

Objectives: The aim of the study was to prospectively evaluate the outcomes of combined LAAO and MTEER.

View Article and Find Full Text PDF

Background: This article focuses on the effect of body mass index (BMI) on cardiac structure and function in cases with non-valvular atrial fibrillation (NVAF). Only a few articles have investigated the relationship between BMI and the incidence of left atrial thrombus (LAT) or spontaneous echo contrast (SEC) in cases with NVAF.

Methods: This single-center retrospective study was conducted at The First People's Hospital of Changzhou.

View Article and Find Full Text PDF

Atrial Cardiomyopathy: From Diagnosis to Treatment.

Rev Cardiovasc Med

January 2025

Department of Cardiology, Renmin Hospital of Wuhan University, 430060 Wuhan, Hubei, China.

With a better understanding of the susceptibility to atrial fibrillation (AF) and the thrombogenicity of the left atrium, the concept of atrial cardiomyopathy (ACM) has emerged. The conventional viewpoint holds that AF-associated hemodynamic disturbances and thrombus formation in the left atrial appendage are the primary causes of cardiogenic embolism events. However, substantial evidence suggests that the relationship between cardiogenic embolism and AF is not so absolute, and that ACM may be an important, underestimated contributor to cardiogenic embolism events.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!